Development and Characterization of the [ 177 Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c01285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Chenkai Mao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province 215000, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Lutetium, Single-Domain Antibodies, Radioisotopes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Second Affiliated Hospital of Soochow University, Gusu health talent research Fund.
Abstract (Originalsprache)
Cadherin 17 (CDH17) is highly expressed in digestive system cancers, and the potential of nanobodies targeting CDH17 as imaging probes and delivery vehicles for radioactive β-particles warrants exploration for their theranostic potential in CDH17-overexpressing gastric cancer (GC). In this study, we screened an anti-CDH17 nanobody library and constructed two antibodies: anti-CDH17 VHH (recombinant nanobody fused with a polyhistidine tag) and anti-CDH17 VHH-ABD (recombinant nanobody fused with an albumin-binding domain). VHH targeting CDH17 and its derivative VHH-ABD were conjugated with DOTA and labeled with radionuclide 177Lu. The pharmacokinetics and theranostic efficacy of these agents were evaluated in the GC xenograft models. [177Lu]Lu-VHH and [177Lu]Lu-VHH-ABD exhibited high radiochemical purity (>99%, n = 3) and successfully delineated CDH17-positive gastric cancer tissues on SPECT/CT imaging. Compared with the rapid renal clearance of [177Lu]Lu-VHH, [177Lu]Lu-VHH-ABD demonstrated prolonged circulation times with increased and sustained tumor accumulation. Survival experiments in the MKN-45 tumor model revealed that two doses of [177Lu]Lu-VHH-ABD effectively suppressed tumor growth, with limited systemic biotoxicity. Histological analysis using hematoxylin and eosin (H&E) staining and Ki67 immunohistochemistry confirmed structural disruption and low tumor cell proliferative activity in the tumor tissue. In preclinical studies, [177Lu]Lu-anti-CDH17 VHH-ABD demonstrated substantial antitumor efficacy with manageable toxicity, offering promising clinical potential as a viable therapeutic option for CDH17-overexpressing GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province 215000, China.
- Department of General Practice, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
- Department of Ultrasound, Shenzhen Children's Hospital, Shenzhen Pediatrics Institute of Shantou University Medical College, No. 7019, Yitian Road, Futian District, Shenzhen 518026, P.R. China.
ORCID-Profile: Zhixiang Zhuang
Förderung
- Second Affiliated Hospital of Soochow University
- Gusu health talent research Fund
Zitieren
APA
Mao, C., Li, S., Fan, R., Zhang, J., Fan, X., Shentu, Z., Zhuang, Z., & Gan, L. (2025). Development and Characterization of the [ 177 Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01285
Vancouver
Mao C, Li S, Fan R, Zhang J, Fan X, Shentu Z, et al. Development and Characterization of the [ 177 Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01285
BibTeX
@article{Mao2025,
author = {Mao, Chenkai and Li, Shicheng and Fan, Rencai and Zhang, Jiaqi and Fan, Xinying and Shentu, Zhen and Zhuang, Zhixiang and Gan, Lei},
title = {Development and Characterization of the [ 177 Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c01285}
}
EUVIMED